ADVERTISEMENT
CR-33
Effectiveness of a native Type I Collagen matrix plus polyhexamethylene biguanide (PHMB) antimicrobial in the treatment of pressure injuries in a real-world setting
Objective: To analyze the subgroup of Pressure Injuries (PRIs) in the 28 site, prospective, non-interventional, PCMP registry (RESPOND)(a) that evaluated the real-world effectiveness of PCMP(b) (native Type I Collagen matrix plus PHMB; polyhexamethylene biguanide antimicrobial) on chronic and acute wounds. Methods: PCMP is intended for the management of partial and full thickness wounds (except 3rd degree burns) and as an effective barrier to reduce microbes penetrating through the dressing. All patients (n=307) in RESPOND received PCMP. Male and female patients, ≥18 years with cutaneous wounds not including third degree burns were eligible for participation. Wounds ≥0.2 and
Sponsor
Sponsor name
This study was funded by Organogenesis, Inc., Canton, MA.
Product Information
PuraPly AM®, Organogenesis Inc, Canton, MA
Trademark
(a) RESPOND Registry; Real-World Effectiveness Study of PuraPly AM® on Wounds
(b) PuraPly AM®, Organogenesis Inc, Canton, MA